|
|
Volumn 13, Issue 6, 2014, Pages 413-414
|
|
Next-generation antibodies
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AGN 150998;
BENRALIZUMAB;
BLINATUMOMAB;
BRENTUXIMAB VEDOTIN;
CATUMAXOMAB;
DCDS 4501A;
DCDT 2980S;
ECROMEXIMAB;
GEMTUZUMAB OZOGAMICIN;
GLEMBATUMUMAB VEDOTIN;
IMGATUZUMAB;
KHK 4563;
KW 2871;
LFB R593;
MEDI 551;
MOGAMULIZUMAB;
MONOCLONAL ANTIBODY;
MOR 208;
MP 0112;
OBINUTUZUMAB;
OCARATUZUMAB;
OFATUMUMAB;
PEGDINETANIB;
PERTUZUMAB;
PINATUZUMAB VEDOTIN;
POLATUZUMAB VEDOTIN;
RG 1760;
RG 7593;
RG 7596;
RITUXIMAB;
ROLEDUMAB;
SAR 3419;
TRASTUZUMAB;
TRASTUZUMAB EMTANSINE;
UNCLASSIFIED DRUG;
XMAB 5574;
ANTIBODY;
ANTINEOPLASTIC AGENT;
IMMUNOTOXIN;
LIGAND;
NEW DRUG;
ACUTE GRANULOCYTIC LEUKEMIA;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ALLOIMMUNIZATION;
ANTIBODY DRUG CONJUGATE;
ANTIBODY ENGINEERING;
ARTICLE;
ASTHMA;
BREAST CANCER;
CHRONIC LYMPHATIC LEUKEMIA;
COLORECTAL CANCER;
DRUG MARKETING;
EXUDATIVE MACULAR DEGENERATION;
FOLLICULAR LYMPHOMA;
GLIOBLASTOMA;
HUMAN;
LARGE CELL LYMPHOMA;
LUNG NON SMALL CELL CANCER;
LYMPHOMA;
MALIGNANT ASCITES;
METASTATIC MELANOMA;
MOLECULARLY TARGETED THERAPY;
NONHODGKIN LYMPHOMA;
PERIPHERAL T CELL LYMPHOMA;
PRIORITY JOURNAL;
RETINA MACULA AGE RELATED DEGENERATION;
SOLID TUMOR;
T CELL LEUKEMIA;
ANTIBODY SPECIFICITY;
CHEMISTRY;
CLINICAL TRIAL (TOPIC);
DRUG COST;
DRUG DESIGN;
ECONOMICS;
METABOLISM;
NEOPLASM;
PROTEIN ENGINEERING;
ANTIBODIES;
ANTIBODIES, MONOCLONAL;
ANTIBODY SPECIFICITY;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG COSTS;
DRUG DESIGN;
DRUGS, INVESTIGATIONAL;
HUMANS;
IMMUNOTOXINS;
LIGANDS;
NEOPLASMS;
PROTEIN ENGINEERING;
|
|
EID: 84901933767
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4255 Document Type: Article |
|
Times cited : (41)
|
|
References (2)
|
